Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Stroke
is the second leading cause of death in the world and in South Korea. Ischemic stroke and silent brain infarction (SBI) are complex, multifactorial diseases influenced by multiple genetic and environmental factors. Moderately elevated plasma homocysteine levels are a major risk factor for vascular diseases, including
stroke
and SBI. Folate and vitamin B12 are important regulators of homocysteine metabolism.
Reduced folate carrier
(RFC), a bidirectional anion exchanger, mediates folate delivery to a variety of cells. We selected three known
RFC
-1 polymorphisms (-43C>T, 80A>G, 696T>C) and investigated their relationship to cerebral infarction in the Korean population. We used the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to analyze associations between the three
RFC
-1 polymorphisms, disease status, and folate and homocysteine levels in 584 ischemic
stroke
patients, 353 SBI patients, and 505 control subjects. The frequencies of the
RFC
-1 -43TT, 80GG, and 696CC genotypes differed significantly between the
stroke
and control groups. The
RFC
-1 80A>G substitution was also associated with small artery occlusion and SBI. In a gene-environment analysis, the
RFC
-1 -43C>T, 80A>G, and 696T>C polymorphisms in the ischemic
stroke
group had combined effects with all environmental factors. In summary, we found that the
RFC
-1 -43C>T, 80A>G, and 696T>C polymorphisms may be risk factors for ischemic
stroke
.
...
PMID:Association of reduced folate carrier-1 (RFC-1) polymorphisms with ischemic stroke and silent brain infarction. 2565 99